Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00226980 · ClinicalTrials.gov registry record · Phase 2
A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00226980: Completed Phase 2 study, sponsored by Stanford University.
NCT00226980 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00226980, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of the combination of thalidomide and capecitabine in metastatic renal cell carcinoma and also to determine the safety of the combination.
Interventions
- DRUG Capecitabine
- DRUG Thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2002-10 |
| Est. Completion | 2006-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00226980
The ClinicalTrials.gov registry entry for NCT00226980 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Capecitabine is the first listed.
NCT00226980 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00226980 about?
NCT00226980 is a clinical study titled "A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma". The purpose of this study is to determine the efficacy of the combination of thalidomide and capecitabine in metastatic renal cell carcinoma and also to determine the safety of the combination.
What is the current status of trial NCT00226980?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2002-10. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00226980?
The interventions under investigation include: Capecitabine (DRUG), Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00226980?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.